INTRODUCTION: Obesity and type 2 Diabetes (T2D) are both associated with greater bone mineral density (BMD) but increased risk of fractures. The effect of the combination of both conditions on bone metabolism, microarchitecture, and strength in the obese population remains unknown. METHODS: Data from 112 obese men were collected. Bone turnover and biochemical markers were measured by enzyme-linked immunosorbent assay, body composition and BMD at all sites were assessed by dual energy X-ray absorptiometry, whereas bone microarchitecture and strength (stiffness and failure load) were measured by high-resolution peripheral computed tomography. Data were compared among metabolically healthy obese (MHO) and metabolically unhealthy obese (MUHO) with and without T2D and between obese without and with T2D. RESULTS: Compared to MHO and MUHO without T2D, MUHO with T2D had significantly lower levels of osteocalcin ((7.49 ± 3.0 and 6.03 ± 2.47 vs 4.24 ± 2.72 ng/mL, respectively, P = 0.003) and C-terminal telopeptide of type I collagen (CTx) (0.28 ± 0.10 and 0.29 ± 0.13 vs 0.21 ± 0.15 ng/mL, respectively, P = 0.02). Dividing our subjects simply into those with and without T2D showed that obese men with T2D had significantly lower levels of osteocalcin (P = 0.003) and CTx (P = 0.005), greater trabecular separation at the tibia and radius (P = 0.03 and P = 0.04, respectively), and lower tibial failure load and stiffness (both P = 0.04), relative to obese men without T2D. CONCLUSION: In men, the combination of obesity and T2D is associated with reduced bone turnover and poorer trabecular bone microarchitecture and bone strength compared to those who are obese but without T2D, suggesting worse bone disease. Published by Oxford University Press on behalf of the Endocrine Society 2021.
INTRODUCTION: Obesity and type 2 Diabetes (T2D) are both associated with greater bone mineral density (BMD) but increased risk of fractures. The effect of the combination of both conditions on bone metabolism, microarchitecture, and strength in the obese population remains unknown. METHODS: Data from 112 obese men were collected. Bone turnover and biochemical markers were measured by enzyme-linked immunosorbent assay, body composition and BMD at all sites were assessed by dual energy X-ray absorptiometry, whereas bone microarchitecture and strength (stiffness and failure load) were measured by high-resolution peripheral computed tomography. Data were compared among metabolically healthy obese (MHO) and metabolically unhealthy obese (MUHO) with and without T2D and between obese without and with T2D. RESULTS: Compared to MHO and MUHO without T2D, MUHO with T2D had significantly lower levels of osteocalcin ((7.49 ± 3.0 and 6.03 ± 2.47 vs 4.24 ± 2.72 ng/mL, respectively, P = 0.003) and C-terminal telopeptide of type I collagen (CTx) (0.28 ± 0.10 and 0.29 ± 0.13 vs 0.21 ± 0.15 ng/mL, respectively, P = 0.02). Dividing our subjects simply into those with and without T2D showed that obese men with T2D had significantly lower levels of osteocalcin (P = 0.003) and CTx (P = 0.005), greater trabecular separation at the tibia and radius (P = 0.03 and P = 0.04, respectively), and lower tibial failure load and stiffness (both P = 0.04), relative to obese men without T2D. CONCLUSION: In men, the combination of obesity and T2D is associated with reduced bone turnover and poorer trabecular bone microarchitecture and bone strength compared to those who are obese but without T2D, suggesting worse bone disease. Published by Oxford University Press on behalf of the Endocrine Society 2021.
Entities:
Keywords:
bone microarchitecture; diabetes mellitus; obesity; osteoporosis
Authors: Ann V Schwartz; Eric Vittinghoff; Douglas C Bauer; Teresa A Hillier; Elsa S Strotmeyer; Kristine E Ensrud; Meghan G Donaldson; Jane A Cauley; Tamara B Harris; Annemarie Koster; Catherine R Womack; Lisa Palermo; Dennis M Black Journal: JAMA Date: 2011-06-01 Impact factor: 56.272
Authors: Hélder Fonseca; Daniel Moreira-Gonçalves; Hans-Joachim Appell Coriolano; José Alberto Duarte Journal: Sports Med Date: 2014-01 Impact factor: 11.136
Authors: N Napoli; R Faccio; V Shrestha; S Bucchieri; G Battista Rini; R Armamento-Villareal Journal: Calcif Tissue Int Date: 2007-04-04 Impact factor: 4.333
Authors: Jana V van Vliet-Ostaptchouk; Marja-Liisa Nuotio; Sandra N Slagter; Dany Doiron; Krista Fischer; Luisa Foco; Amadou Gaye; Martin Gögele; Margit Heier; Tero Hiekkalinna; Anni Joensuu; Christopher Newby; Chao Pang; Eemil Partinen; Eva Reischl; Christine Schwienbacher; Mari-Liis Tammesoo; Morris A Swertz; Paul Burton; Vincent Ferretti; Isabel Fortier; Lisette Giepmans; Jennifer R Harris; Hans L Hillege; Jostein Holmen; Antti Jula; Jenny E Kootstra-Ros; Kirsti Kvaløy; Turid Lingaas Holmen; Satu Männistö; Andres Metspalu; Kristian Midthjell; Madeleine J Murtagh; Annette Peters; Peter P Pramstaller; Timo Saaristo; Veikko Salomaa; Ronald P Stolk; Matti Uusitupa; Pim van der Harst; Melanie M van der Klauw; Melanie Waldenberger; Markus Perola; Bruce Hr Wolffenbuttel Journal: BMC Endocr Disord Date: 2014-02-01 Impact factor: 2.763
Authors: Elliot Ballato; F N U Deepika; Vittoria Russo; Alcibiades Fleires-Gutiérrez; Georgia Colleluori; Virginia Fuenmayor; Rui Chen; Dennis T Villareal; Clifford Qualls; Reina Armamento-Villareal Journal: Calcif Tissue Int Date: 2022-06-04 Impact factor: 4.000
Authors: Elliot Ballato; Fnu Deepika; Mia Prado; Vittoria Russo; Virginia Fuenmayor; Siresha Bathina; Dennis T Villareal; Clifford Qualls; Reina Armamento-Villareal Journal: Front Endocrinol (Lausanne) Date: 2022-09-12 Impact factor: 6.055